<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Annals of Clinical and Experimental Neurology</journal-id><journal-title-group><journal-title xml:lang="en">Annals of Clinical and Experimental Neurology</journal-title><trans-title-group xml:lang="ru"><trans-title>Анналы клинической и экспериментальной неврологии</trans-title></trans-title-group></journal-title-group><issn publication-format="print">2075-5473</issn><issn publication-format="electronic">2409-2533</issn><publisher><publisher-name xml:lang="en">Eco-Vector</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1479</article-id><article-id pub-id-type="doi">10.17816/ACEN.1479</article-id><article-id pub-id-type="edn">CEDYYR</article-id><article-categories><subj-group subj-group-type="toc-heading" xml:lang="en"><subject>Original articles</subject></subj-group><subj-group subj-group-type="toc-heading" xml:lang="ru"><subject>Оригинальные статьи</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">MicroRNA expression in circulating exosomes as potential cerebral atherosclerosis biomarkers: comparative profiling study</article-title><trans-title-group xml:lang="ru"><trans-title>МикроРНК в циркулирующих экзосомах как потенциальные биомаркеры церебрального атеросклероза: результаты сравнительного профилирования</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-0522-767X</contrib-id><name-alternatives><name xml:lang="en"><surname>Raskurazhev</surname><given-names>Anton A.</given-names></name><name xml:lang="ru"><surname>Раскуражев</surname><given-names>Антон Алексеевич</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), Head, Laboratory of neuropharmacological fMRI, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, рук. лаб. нейрофармакологической фМРТ Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-7393-0979</contrib-id><name-alternatives><name xml:lang="en"><surname>Shabalina</surname><given-names>Аlla А.</given-names></name><name xml:lang="ru"><surname>Шабалина</surname><given-names>Алла Анатольевна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci. (Med), leading researcher, Head, Laboratory diagnostics department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, в. н. с., рук. отдела лабораторной диагностики Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-4626-6520</contrib-id><name-alternatives><name xml:lang="en"><surname>Kuznetsova</surname><given-names>Polina I.</given-names></name><name xml:lang="ru"><surname>Кузнецова</surname><given-names>Полина Игоревна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), senior researcher, 1<sup>st</sup> Neurological department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, с. н. с. 1-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9120-2550</contrib-id><name-alternatives><name xml:lang="en"><surname>Annushkin</surname><given-names>Vladislav A.</given-names></name><name xml:lang="ru"><surname>Аннушкин</surname><given-names>Владислав Александрович</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Cand. Sci. (Med.), neurologist, 1<sup>st</sup> Neurological department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>канд. мед. наук, врач-невролог 1-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5883-8119</contrib-id><name-alternatives><name xml:lang="en"><surname>Tanashyan</surname><given-names>Marine M.</given-names></name><name xml:lang="ru"><surname>Танашян</surname><given-names>Маринэ Мовсесовна</given-names></name></name-alternatives><address><country country="RU">Russian Federation</country></address><bio xml:lang="en"><p>Dr. Sci (Med), Professor, Full Member of RAS, Deputy Director for Science, Head, 1<sup>st</sup> Neurological Department, Institute of Clinical and Preventive Neurology</p></bio><bio xml:lang="ru"><p>д-р мед. наук, профессор, академик РАН, зам. директора по научной работе, рук. 1-го неврологического отделения Института клинической и профилактической неврологии</p></bio><email>annaly-nevrologii@neurology.ru</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff-alternatives id="aff1"><aff><institution xml:lang="en">Russian Center of Neurology and Neurosciences</institution></aff><aff><institution xml:lang="ru">Российский центр неврологии и нейронаук</institution></aff></aff-alternatives><pub-date date-type="pub" iso-8601-date="2026-04-07" publication-format="electronic"><day>07</day><month>04</month><year>2026</year></pub-date><volume>20</volume><issue>1</issue><issue-title xml:lang="en"/><issue-title xml:lang="ru"/><fpage>8</fpage><lpage>18</lpage><history><date date-type="received" iso-8601-date="2026-01-28"><day>28</day><month>01</month><year>2026</year></date><date date-type="accepted" iso-8601-date="2026-02-25"><day>25</day><month>02</month><year>2026</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2026, Raskurazhev A.A., Shabalina А.А., Kuznetsova P.I., Annushkin V.A., Tanashyan M.M.</copyright-statement><copyright-statement xml:lang="ru">Copyright ©; 2026, Раскуражев А.А., Шабалина А.А., Кузнецова П.И., Аннушкин В.А., Танашян М.М.</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="en">Raskurazhev A.A., Shabalina А.А., Kuznetsova P.I., Annushkin V.A., Tanashyan M.M.</copyright-holder><copyright-holder xml:lang="ru">Раскуражев А.А., Шабалина А.А., Кузнецова П.И., Аннушкин В.А., Танашян М.М.</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/">https://creativecommons.org/licenses/by/4.0</ali:license_ref></license></permissions><self-uri xlink:href="https://annaly-nevrologii.com/pathID/article/view/1479">https://annaly-nevrologii.com/pathID/article/view/1479</self-uri><abstract xml:lang="en"><p><bold>Introduction. </bold>Cerebral atherosclerosis (CA) remains a leading cause of ischemic cerebrovascular diseases, while molecular markers characterizing the activity and mechanisms of atherogenesis in cerebral arteries are insufficiently studied. Exosomal microRNA expression may serve as a promising biomarker for CA, reflecting the level of epigenetic regulatory burden.</p> <p>The study <bold>aimed</bold> to identify the CA-associated exosomal microRNA profile and evaluate its potential as biomarkers through comparative profiling.</p> <p><bold>Materials and methods. </bold>This prospective study included inpatients of the Research Center of Neurology and Neurosciences: a CA group (n = 43; median age 68 years) with extra-/intracranial atherosclerosis confirmed by angiographic imaging, and a control group with non-atherosclerotic cerebrovascular diseases (n = 17; median age 46 years). Exosomes and exosomal RNA were isolated from blood serum (ExoQuick), followed by amplification (SeraMir) and profiling of 384 microRNAs via real-time PCR. After quality control, 337 endogenous microRNAs were retained for analysis. Normalization was performed using the global mean method with ΔCt calculation; differential expression was assessed with limma (empirical Bayes correction), with significance thresholds set at adjusted p-value &lt; 0.1 and |log<sub>2</sub>FC| &gt; 0.5. Additionally, a network analysis of microRNA-target genes (miRTarBase/MIENTURNET) with functional annotation was conducted.</p> <p><bold>Results. </bold>Patients with CA exhibited 9 exosomal microRNAs with statistically significant differential expression, with all changes being unidirectional — a decrease of microRNA levels in the CA group: hsa-miR-18a, hsa-miR-539, hsa-miR-20a, hsa-miR-100, hsa-miR-10b, hsa-let-7f, hsa-miR-148b, hsa-miR-187, hsa-miR-374a. Visualization of the top 30 microRNAs with the smallest adjusted p-value revealed a consistent trend toward lower expression in patients with CA, and sample clustering generally corresponded to clinical groups. Network analysis identified hub genes potentially involved in endothelial dysfunction and epigenetic regulation (DNMT1, MSL3, SMCHD1), lipid metabolism and anti-inflammatory signaling (RORA, NCOA6), oxidative stress/macrophage activation (SESN3), vascular smooth muscle cell proliferation (CCND1, CTDSPL2), and cell migration and vascular remodeling (PAFAH1B1, BTBD7).</p> <p><bold>Conclusion. </bold>Cerebral atherosclerosis is associated with a unidirectional decrease in the expression of several microRNAs in circulating exosomes. These findings indicate the potential role of exosomal microRNAs in the CA molecular mechanisms and justify further investigation into their diagnostic and pathogenetic significance.</p></abstract><trans-abstract xml:lang="ru"><p><bold>Введение. </bold>Церебральный атеросклероз (ЦА) остаётся одной из ведущих причин ишемических цереброваскулярных заболеваний, при этом молекулярные маркеры, характеризующие активность и механизмы атерогенеза в церебральных артериях, изучены недостаточно. Экзосомальная экспрессия микроРНК может являться перспективным биомаркером ЦА, отражающим уровень эпигенетической регуляторной нагрузки.</p> <p><bold>Цель </bold>исследования<bold> </bold>— выявить профиль экзосомальных микроРНК, ассоциированный с ЦА, и оценить их потенциал в качестве биомаркеров на основе сравнительного профилирования.</p> <p><bold>Материалы и методы. </bold>В проспективное исследование включены пациенты стационара РЦНН: группа ЦА (n = 43; медиана возраста 68 лет) с атеросклерозом экстра/интракраниальных артерий по данным ангиовизуализации и группа сравнения с неатеросклеротическими формами цереброваскулярной патологии (n = 17; медиана возраста 46 лет). Из сыворотки крови выделяли экзосомы и экзосомальную РНК («ExoQuick»), выполняли амплификацию (SeraMir) и профилирование 384 микроРНК методом ПЦР в реальном времени. После контроля качества для анализа сохранены 337 эндогенных микроРНК. Нормализацию проводили методом глобального среднего с расчётом ΔCt; дифференциальную экспрессию оценивали с использованием limma (эмпирическая байесовская коррекция), критерии значимости: скорректированное значение p &lt; 0,1 и |log<sub>2</sub>FC| &gt; 0,5. Дополнительно выполнен сетевой анализ микроРНК–таргетных генов (miRTarBase/MIENTURNET) с функциональной аннотацией.</p> <p><bold>Результаты. </bold>У пациентов с ЦА выявлены 9 экзосомальных микроРНК со статистически значимой дифференциальной экспрессией, причём во всех случаях изменения были однонаправленными — снижение уровня в группе ЦА: hsa-miR-18a, hsa-miR-539, hsa-miR-20a, hsa-miR-100, hsa-miR-10b, hsa-let-7f, hsa-miR-148b, hsa-miR-187, hsa-miR-374a. При визуализации топ-30 микроРНК с минимальным скорректированным значением p наблюдалась единая тенденция к более низкой экспрессии у пациентов с ЦА, а кластеризация образцов в целом соответствовала клиническим группам. Сетевой анализ указал на гены-хабы, потенциально вовлечённые в эндотелиальную дисфункцию и эпигенетическую регуляцию (DNMT1, MSL3, SMCHD1), липидный обмен и противовоспалительный сигналинг (RORA, NCOA6), окислительный стресс/активацию макрофагов (SESN3), пролиферацию гладкомышечных клеток сосудов (CCND1, CTDSPL2), клеточную миграцию и сосудистое ремоделирование (PAFAH1B1, BTBD7).</p> <p><bold>Заключение. </bold>Церебральный атеросклероз ассоциирован с однонаправленным снижением экспрессии ряда микроРНК в составе циркулирующих экзосом. Полученные данные указывают на потенциальную роль экзосомальных микроРНК в молекулярных механизмах ЦА и обосновывают целесообразность дальнейших исследований их диагностического и патогенетического значения.</p></trans-abstract><kwd-group xml:lang="en"><kwd>cerebral atherosclerosis</kwd><kwd>microRNA</kwd><kwd>circulating exosomes</kwd><kwd>biomarkers</kwd></kwd-group><kwd-group xml:lang="ru"><kwd>церебральный атеросклероз</kwd><kwd>микроРНК</kwd><kwd>циркулирующие экзосомы</kwd><kwd>биомаркеры</kwd></kwd-group><funding-group><award-group><funding-source><institution-wrap><institution xml:lang="en">Ministry of Science and Higher Education of the Russian Federation</institution></institution-wrap><institution-wrap><institution xml:lang="ru">Министерство науки и высшего образования Российской Федерации</institution></institution-wrap></funding-source><award-id>075-15-2024-638</award-id></award-group><funding-statement xml:lang="en">This work was supported by a grant from the Ministry of Science and Higher Education of the Russian Federation for major scientific projects in priority areas of scientific and technological development (project # 075-15-2024-638).</funding-statement><funding-statement xml:lang="ru">Грант Минобрнауки России на проведение крупных научных проектов по приоритетным направлениям научно-технологического развития, соглашение № 075-15-2024-638.</funding-statement></funding-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>Libby P, Ridker PM, Hansson GK. Progress and challenges in translating the biology of atherosclerosis. Nature. 2011;473(7347):317–325. doi: 10.1038/nature10146</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Zhu Y, Hu Z, Liu J, et al. Epigenetic-ncRNA crosstalk in atherosclerosis: mechanisms, disease progression and therapeutic potential (Review). Int J Mol Med. 2025;56(5):180. doi: 10.3892/ijmm.2025.5621</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Tanashyan MM, Shabalina AA, Annushkin VA, et al. Circulating microRNAs in carotid atherosclerosis: complex interplay and possible associations with atherothrombotic stroke. Int J Mol Sci. 2024;25(18):10026. doi: 10.3390/ijms251810026</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Раскуражев А.А., Шабалина А.А., Кузнецова П.И., Танашян М.М. МикроРНК как значимые биомаркеры атеросклеротической цереброваскулярной патологии. Анналы клинической и экспериментальной неврологии. 2022;16(1):5–13. / Raskurazhev AA, Shabalina AA, Kuznetsova PI, Tanashyan MM. MicroRNA as significant biomarkers of cerebrovascular atherosclerosis. Annals of Clinical and Experimental Neurology. 2022;16(1):5–13. doi: 10.54101/ACEN.2022.1.1</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Chen YF, Luh F, Ho YS, Yen Y. Exosomes: a review of biologic function, diagnostic and targeted therapy applications, and clinical trials. J Biomed Sci. 2024;31(1):67. doi: 10.1186/s12929-024-01055-0</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Lee KWA, Chan LKW, Hung LC, et al. Clinical applications of exosomes: a critical review. Int J Mol Sci. 2024;25(14):7794. doi: 10.3390/ijms25147794</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Rizzuto AS, Fichtner I, Carugo S, et al. The role of extracellular vesicle–derived mirna in the atherosclerotic burden. Am J Pathol. 2025;195(12):2274–2287. doi: 10.1016/j.ajpath.2025.08.006</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Letonja J, Petrovič D. A review of microRNAs and lncRNAs in atherosclerosis as well as some major inflammatory conditions affecting atherosclerosis. Biomedicines. 2024;12(6):1322. doi: 10.3390/biomedicines12061322</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Peña-Peña M, Zepeda-García Ó, Posadas-Sánchez R, et al. A plasma extracellular vesicle-derived microrna signature as a potential biomarker for subclinical coronary atherosclerosis. Int J Mol Sci. 2025;26(17):8727. doi: 10.3390/ijms26178727</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Kee HJ, Kim GR, Cho SN, et al. miR-18a-5p microRNA increases vascular smooth muscle cell differentiation by downregulating Syndecan4. Korean Circ J. 2014;44(4):255–263. doi: 10.4070/kcj.2014.44.4.255</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Teng P, Liu Y, Zhang M, Ji W. Diagnostic and prognostic significance of serum miR-18a-5p in patients with atherosclerosis. Clin Appl Thromb Off J Int Acad Clin Appl Thromb. 2021;27:10760296211050642. doi: 10.1177/10760296211050642</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Lin B, Feng D, Xu J. Cardioprotective effects of microRNA-18a on acute myocardial infarction by promoting cardiomyocyte autophagy and suppressing cellular senescence via brain derived neurotrophic factor. Cell Biosci. 2019;9:38. doi: 10.1186/s13578-019-0297-8</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>Chen M, Li W, Zhang Y, Yang J. MicroRNA-20a protects human aortic endothelial cells from Ox-LDL-induced inflammation through targeting TLR4 and TXNIP signaling. Biomed Pharmacother. 2018;103:191–197. doi: 10.1016/j.biopha.2018.03.129</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>Pankratz F, Hohnloser C, Bemtgen X, et al. MicroRNA-100 suppresses chronic vascular inflammation by stimulation of endothelial autophagy. Circ Res. 2018;122(3):417–432. doi: 10.1161/CIRCRESAHA.117.311428</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>Tanashyan MM, Raskurazhev AA, Shabalina AA, et al. Differential pattern of circulating microRNA expression in patients with intracranial atherosclerosis. Biomedicines. 2025;13(2):514. doi: 10.3390/biomedicines13020514</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Kowara M, Kopka M, Kopka K, et al. MicroRNA inhibiting atheroprotective proteins in patients with unstable angina comparing to chronic coronary syndrome. Int J Mol Sci. 2024;25(19):10621. doi: 10.3390/ijms251910621</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Jiang H, Toscano JF, Song SS, et al. Differential expression of circulating exosomal microRNAs in refractory intracranial atherosclerosis associated with antiangiogenesis. Sci Rep. 2019;9(1):19429. doi: 10.1038/s41598-019-54542-y</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Egea V, Megens RTA, Santovito D, et al. Properties and fate of human mesenchymal stem cells upon miRNA let-7f-promoted recruitment to atherosclerotic plaques. Cardiovasc Res. 2023;119(1):155–166. doi: 10.1093/cvr/cvac022</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Santovito D, De Nardis V, Marcantonio P, et al. Plasma exosome microRNA profiling unravels a new potential modulator of adiponectin pathway in diabetes: effect of glycemic control. J Clin Endocrinol Metab. 2014;99(9):E1681–1685. doi: 10.1210/jc.2013-3843</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Zhang X, Shi H, Wang Y, et al. Down-regulation of hsa-miR-148b inhibits vascular smooth muscle cells proliferation and migration by directly targeting HSP90 in atherosclerosis. Am J Transl Res. 2017;9(2):629–637.</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Zhang Y, Tang Y, Yan J. LncRNA-XIST Promotes proliferation and migration in ox-LDL stimulated vascular smooth muscle cells through miR-539-5p/SPP1 axis. Oxid Med Cell Longev. 2022;2022:9911982. doi: 10.1155/2022/9911982</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Rossato M, Curtale G, Tamassia N, et al. IL-10-induced microRNA-187 negatively regulates TNF-α, IL-6, and IL-12p40 production in TLR4-stimulated monocytes. Proc Natl Acad Sci U S A. 2012;109(45):E3101–3110. doi: 10.1073/pnas.1209100109</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Wang W, Ma F, Zhang H. MicroRNA-374 is a potential diagnostic biomarker for atherosclerosis and regulates the proliferation and migration of vascular smooth muscle cells. Cardiovasc Diagn Ther. 2020;10(4):687–694. doi: 10.21037/cdt-20-444</mixed-citation></ref></ref-list></back></article>
